Denver Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Denver Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$412K	Buy	13,216 +664	+5%	+$23.6K	0.02%	345
2017 Q4	$573K	Buy	12,552 +5,692	+83%	+$226K	0.03%	303
2017 Q3	$258K	Buy	6,860 +10	+0.1%	+$402	0.01%	398
2017 Q2	$327K	Buy	6,850 +435	+7%	+$20.2K	0.01%	372
2017 Q1	$293K	Sell	6,415 -210	-3%	-$9.08K	0.01%	398
2016 Q4	$214K	Buy	+6,625	New	+$221K	0.01%	441
2015 Q3	–	Sell	-4,970	Closed	-$351K	–	561
2015 Q2	$351K	Sell	4,970 -41,861	-89%	-$3.3M	0.01%	405
2015 Q1	$4.16M	Buy	46,831 +1,710	+4%	+$173K	0.14%	174
2014 Q4	$4M	Buy	45,121 +20,062	+80%	+$1.9M	0.13%	174
2014 Q3	$2.43M	Sell	25,059 -886	-3%	-$86.2K	0.08%	252
2014 Q2	$2.38M	Buy	+25,945	New	+$1.98M	0.07%	269

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Denver Investment Advisors's PCRX Position: Q1 2018 in Review

Denver Investment Advisors increased its Pacira BioSciences (PCRX) stake by 5.3% in Q1 2018, buying an estimated $23.6K and bringing the position to 13,216 shares worth $412K. The position accounts for 0.02% of the portfolio, ranked #345.

Denver Investment Advisors first reported a position in PCRX in Q2 2014 and has held it in 11 quarters since. The position peaked at $4.16M in Q1 2015. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

Denver Investment Advisors held 13,216 shares of Pacira BioSciences worth $412K as of Q1 2018.
Denver Investment Advisors bought 664 Pacira BioSciences shares in Q1 2018, an estimated $23.6K.
Pacira BioSciences made up 0.02% of Denver Investment Advisors's portfolio in Q1 2018, its #345 holding.
Denver Investment Advisors first reported a position in Pacira BioSciences in Q2 2014 and has held it in 11 quarters since.
Denver Investment Advisors's Pacira BioSciences position peaked at $4.16M in Q1 2015.
168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Denver Investment Advisors's 13F filing for Q1 2018, filed 10 May 2018.